191 related articles for article (PubMed ID: 34853086)
1. Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
van der Heijde D; Østergaard M; Reveille JD; Baraliakos X; Kronbergs A; Sandoval DM; Li X; Carlier H; Adams DH; Maksymowych WP
J Rheumatol; 2022 Mar; 49(3):265-273. PubMed ID: 34853086
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis.
Llop M; Rios Rodriguez V; Redeker I; Sieper J; Haibel H; Rudwaleit M; Poddubnyy D
Arthritis Res Ther; 2019 May; 21(1):126. PubMed ID: 31126334
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
[TBL] [Abstract][Full Text] [Related]
4. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
van der Horst-Bruinsma IE; de Vlam K; Walsh JA; Bolce R; Hunter T; Sandoval D; Zhu D; Geneus V; Soriano ER; Magrey M
Adv Ther; 2022 Jun; 39(6):2806-2819. PubMed ID: 35429281
[TBL] [Abstract][Full Text] [Related]
5. Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis.
Braun J; Blanco R; Marzo-Ortega H; Gensler LS; Van den Bosch F; Hall S; Kameda H; Poddubnyy D; van de Sande M; van der Heijde D; Zhuang T; Stefanska A; Readie A; Richards HB; Deodhar A
Arthritis Res Ther; 2023 May; 25(1):80. PubMed ID: 37194094
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
Braun J; Kiltz U; Deodhar A; Tomita T; Dougados M; Bolce R; Sandoval D; Lin CY; Walsh J
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35853675
[TBL] [Abstract][Full Text] [Related]
7. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis.
Poddubnyy D; Haibel H; Listing J; Märker-Hermann E; Zeidler H; Braun J; Sieper J; Rudwaleit M
Arthritis Rheum; 2012 May; 64(5):1388-98. PubMed ID: 22127957
[TBL] [Abstract][Full Text] [Related]
8. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
van der Heijde D; Baraliakos X; Hermann KA; Landewé RBM; Machado PM; Maksymowych WP; Davies OR; de Peyrecave N; Hoepken B; Bauer L; Nurminen T; Braun J
Ann Rheum Dis; 2018 May; 77(5):699-705. PubMed ID: 29343510
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
Maksymowych WP; Bolce R; Gallo G; Seem E; Geneus VJ; Sandoval DM; Østergaard M; Tada K; Baraliakos X; Deodhar A; Gensler LS
Rheumatology (Oxford); 2022 Nov; 61(11):4324-4334. PubMed ID: 35188180
[TBL] [Abstract][Full Text] [Related]
10. Site-specific assessment of spinal radiographic progression improves detection of TNF blocker-associated disease modification in axial spondyloarthritis: longitudinal observational data from the Swiss Clinical Quality Management Registry.
Popova V; Kissling S; Micheroli R; Bräm R; de Hooge M; Baraliakos X; Nissen MJ; Möller B; Exer P; Andor M; Distler O; Scherer A; Ospelt C; Ciurea A
Arthritis Res Ther; 2023 Mar; 25(1):40. PubMed ID: 36915202
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis.
Poddubnyy D; Conrad K; Haibel H; Syrbe U; Appel H; Braun J; Rudwaleit M; Sieper J
Ann Rheum Dis; 2014 Dec; 73(12):2137-43. PubMed ID: 23956246
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).
Baraliakos X; Østergaard M; Gensler LS; Poddubnyy D; Lee EY; Kiltz U; Martin R; Sawata H; Readie A; Porter B;
Clin Drug Investig; 2020 Mar; 40(3):269-278. PubMed ID: 31983056
[TBL] [Abstract][Full Text] [Related]
13. Can whole spine magnetic resonance imaging predict radiographic progression and inflammatory activity in axial spondyloarthritis?
Kim JG; Jung JY; Lee J; Kwok SK; Ju JH; Park SH; Kim WU
Joint Bone Spine; 2022 Jul; 89(4):105352. PubMed ID: 35124211
[TBL] [Abstract][Full Text] [Related]
14. Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO.
Llop M; Moreno M; Navarro-Compán V; Juanola X; de Miguel E; Almodóvar R; Quintana EC; Sanz JS; Beltrán E; Montesinos MDR; Calvet J; Berenguer-Llergo A; Gratacós J;
Arthritis Res Ther; 2022 Jan; 24(1):30. PubMed ID: 35063018
[TBL] [Abstract][Full Text] [Related]
15. Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
Braun J; Buehring B; Baraliakos X; Gensler LS; Porter B; Quebe-Fehling E; Haemmerle S
BMC Musculoskelet Disord; 2021 Dec; 22(1):1037. PubMed ID: 34903218
[TBL] [Abstract][Full Text] [Related]
16. Spinal radiographic progression in axial spondyloarthritis and the impact of classification as nonradiographic versus radiographic disease: Data from the Swiss Clinical Quality Management cohort.
Hebeisen M; Micheroli R; Scherer A; Baraliakos X; de Hooge M; van der Heijde D; Landewé R; Bürki K; Nissen MJ; Möller B; Zufferey P; Exer P; Ciurea A
PLoS One; 2020; 15(3):e0230268. PubMed ID: 32196530
[TBL] [Abstract][Full Text] [Related]
17. Quantitative prediction of radiographic progression in patients with axial spondyloarthritis using neural network model in a real-world setting.
Baek IW; Jung SM; Park YJ; Park KS; Kim KJ
Arthritis Res Ther; 2023 Apr; 25(1):65. PubMed ID: 37081563
[TBL] [Abstract][Full Text] [Related]
18. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years.
van der Heijde D; Salonen D; Weissman BN; Landewé R; Maksymowych WP; Kupper H; Ballal S; Gibson E; Wong R; ;
Arthritis Res Ther; 2009; 11(4):R127. PubMed ID: 19703304
[TBL] [Abstract][Full Text] [Related]
19. Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab.
Braun J; Baraliakos X; Hermann KG; Xu S; Hsu B
J Rheumatol; 2016 Sep; 43(9):1704-12. PubMed ID: 27422890
[TBL] [Abstract][Full Text] [Related]
20. Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada cohort.
Haroon N; Maksymowych WP; Rahman P; Tsui FW; O'Shea FD; Inman RD
Arthritis Rheum; 2012 Apr; 64(4):1119-26. PubMed ID: 22034108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
